Cancer and Connection: Where It All Began

Long before Comedy vs Cancer became a marquee fundraising event, it began in a far quieter setting. A waiting room in 2007. Two women. Both young. Both bald. Both are facing blood cancer.

Jennifer Rogers Carlock and Niccole Kroll did not meet under ideal circumstances, but they met in a way that forged something rare and enduring.

“We both understood exactly what was at stake, even if we had no idea where our lives, or our families’ lives, would be six months later,” said Kroll, co-founder of Comedy vs Cancer. “There was a shared uncertainty, but also a shared sense of hope and comfort, knowing we were being treated at Memorial Sloan Kettering Cancer Center, one of the best cancer institutions in the country, and that we were receiving the most advanced therapies.”

What they recognized in each other required no explanation. The loss of control. The disruption of time. The quiet sacrifices made by loved ones trying to keep life steady for young children. The invisible weight of it all.

Carlock described it with striking clarity. “There is something about having a baby or a very young child and being diagnosed with cancer. Babies are so full of life. And then there we are, bald, maybe closer to the end than we are supposed to be. It’s so far off the bingo card of what you thought your life as a mother would be.”

From that shared moment, something lasting took shape.

Cancer and Comedy: An Unexpected but Essential Pairing

Comedy vs Cancer, now a star-studded annual benefit that has raised almost $10 million for MSK physician-scientists, was never meant to minimize the seriousness of cancer. Instead, it reframed how people move through it.

“In my family, humor is never something to be ashamed of, no matter the moment,” Kroll shared. “It’s a tool we rely on to get through the hardest times.”

She recalled visiting her father during his second battle with acute myeloid leukemia. Even in the hospital, even while critically ill, he chose to watch comedy.

“I have a photo of him in his hospital bed, hooked up to an IV, with the biggest smile on his face,” she said. “It’s an image I’ll never forget.”

That image carries the essence of Comedy vs Cancer. Laughter does not erase fear, but it creates space within it. It allows for a breath. A pause. A moment of relief that can feel monumental.

Carlock echoed that balance. “People can go from laughing to crying and back to laughing in one night. It’s the human condition. We all experience joy, tragedy, love, and loss. We just pack it into a two-hour show.”

That emotional range has become part of the event’s signature, featuring performers like Tina Fey, Hasan Minhaj, John Oliver, and Sarah Silverman, alongside powerful stories from patients and physicians.

Cancer and Responsibility: When Personal Becomes Public

What began as something deeply personal eventually grew into something far larger.

“There wasn’t a single moment,” said Kroll. “It was a gradual shift.”

As Comedy vs Cancer expanded, raising more funds and reaching wider audiences, the stakes evolved. The responsibility became tangible. Decisions about where funding would go were no longer abstract.

“We weren’t just raising money,” she explained. “We were entrusted with directing it in ways that could directly impact lives.”

That shift crystallized during their first allocations meeting, where funds raised were used to support clinical trials. The weight of those decisions was undeniable.

Carlock described a pivotal realization. “After we allocated the money raised from the very first show, I realized that this could make a real difference.”

She pointed to a trial supported by Comedy vs Cancer that was nearly shelved. Funding from the event enabled researchers to treat five patients, leading to further investment from a pharmaceutical partner and recognition on the cover of Blood, a leading hematology journal.

“That keeps me going,” she said. “When you see how hard the doctors and researchers are working, it just makes you want to raise more.”

Cancer and Innovation: How AI Is Changing the Future

The Spring Ball’s 2026 initiative highlighted one of the most promising developments in oncology: the integration of artificial intelligence into cancer research.

According to Memorial Sloan Kettering’s computational oncology work, AI is helping researchers refine precision medicine, detect early signs of cancer and recurrence, and better understand how tumors evolve.

Dr. Sohrab Shah’s research is at the forefront of this movement, combining vast datasets with advanced computational models to identify patterns that would be impossible to detect through traditional methods alone.

This matters deeply when considering the broader landscape. In 2026, more than 2.1 million new cancer cases and over 600,000 deaths are projected in the United States, according to SEER cancer statistics. While survival rates have improved, with a five-year survival rate now reaching 70 percent, disparities remain, particularly as incidence rises among women.

Emerging research published in Nature npj Precision Oncology underscores the potential of AI to close these gaps by enabling earlier detection and more personalized treatment pathways.

This is where philanthropy becomes critical.

Cancer and Philanthropy: Fueling What Comes Next

Katie Klein, Vice President of Development Programs at MSK, emphasized how donor engagement has evolved in recent years.

“Donors are educated in what’s going on in the field and are true partners with MSK,” she said. “They provide the resources our scientists need to make meaningful, life-changing advances.”

That partnership goes beyond writing a check. It is about connection. Community. Shared purpose.

“Nearly everyone has been touched by cancer in some way,” Klein noted. “These events create a space to advance progress and celebrate our impact together.”

Philanthropic funding also offers something essential in an increasingly competitive research environment. Flexibility.

“At a time when funding has become less predictable, philanthropy gives MSK the ability to act when time matters most,” Klein explained. “It ensures that promising research can move forward without delay.”

Events like the Spring Ball and Comedy vs Cancer offer donors the opportunity to see the direct impact of their support while building relationships with the scientists and clinicians driving progress.

Cancer, Hope, and What Comes Next

There is a tendency to think of progress in cancer care as something distant, something reserved for labs and clinical trials. But nights like the Spring Ball and initiatives like Comedy vs Cancer bring that progress into sharp, human focus.

They remind us that behind every dataset is a person. Behind every trial is a family waiting. Behind every breakthrough is a community that made it possible.

The stories shared by Jennifer Rogers Carlock and Niccole Kroll are not just about survival. They are about what happens after choosing to build something that extends beyond personal experience and creates lasting impact.

Nearly two decades after meeting in a treatment room, their work continues to ripple outward, supporting research, shaping conversations, and offering a model for how humor and humanity can coexist with even the hardest realities.

As artificial intelligence reshapes the future of cancer care, it is clear that progress will not come from technology alone. It will come from the people who show up. Who give. Who connects. Those who believe that even in the face of uncertainty, there is always something worth building.

In rooms like The Plaza. In hospital waiting areas. In moments of laughter that break through fear of cancer. That is where change begins.